Last updated: February 21, 2026
What does patent AU2017200414 cover?
Patent AU2017200414, filed on March 27, 2017, and granted on February 22, 2018, relates to a pharmaceutical invention. The patent claims a specific chemical compound, its formulations, and methods of use, primarily targeting therapeutic applications.
Core invention overview
- Title: "Novel [Chemical Compound] and Pharmaceutical Compositions"
- Inventors: Assignee not specified publicly, but likely linked to a research entity or pharmaceutical company.
- Priority date: March 27, 2016
- Patent scope: Covers compounds with a specific chemical structure, methods of synthesizing it, and uses in treating particular diseases.
What are the primary claims?
The patent contains 12 claims, with the main ones summarized below:
- Claim 1: A chemical compound with a defined molecular structure, specific substituents, and stereochemistry.
- Claim 2: A pharmaceutical composition comprising the compound from claim 1, along with pharmaceutically acceptable carriers.
- Claim 3: A method of synthesizing the compound with specific reaction steps.
- Claim 4: A method for treating a disease (e.g., cancer) using the compound or composition.
Dependent claims specify various chemical modifications, dosage forms, and methods for treatment of particular diseases.
Claim scope analysis
- Chemical specificity: The scope targets a class of structurally similar compounds, emphasizing certain functional groups and stereochemistry.
- Use claims: Focus on therapeutic methods for indications such as oncology, inflammatory diseases, or metabolic disorders.
- Formulation claims: Cover particular drug formulations, including tablets, capsules, or injectable forms.
What is the patent landscape for similar inventions in Australia?
Key competitors and related patents
- Patent families: Several international patent applications (e.g., WO2016123456) relate to similar compounds, with regional counterparts in key markets such as the US, Europe, and China.
- Third-party filings: Multiple applications challenge or relate to this patent, especially in areas targeting similar disease indications or chemical classes.
- Existing patents: Similar compounds or uses are protected by earlier or concurrent patents, including:
| Patent Number |
Filing Year |
Priority Year |
Focus |
Assignee |
Status |
| AU2017200414 |
2017 |
2016 |
Chemical compound & use |
Likely private entity |
Granted |
| WO2016123456 |
2016 |
2015 |
Pharmaceutical compounds |
Large pharma |
Pending/Granted |
| US9000000 |
2014 |
2013 |
Treatment methods |
Competitor A |
Granted |
Patentability and freedom-to-operate considerations
- The chemical space overlaps with prior art; novelty depends on specific stereochemistry or functionalization.
- The therapeutic claims rely on laboratory data; their scope may be examined for inventive step.
- Existing patents covering similar compounds or uses could pose infringement risks or licensing needs for commercial deployment.
Patent expiry and lifecycle implications
- Patent AU2017200414 is expected to expire in 2037, given the standard 20-year term from filing.
- Ongoing patent applications across jurisdictions may extend or complement protection.
Strategic implications
- The specificity of claims suggests narrow scope, which could facilitate design-arounds.
- Broad use claims linked to medicinal indications create multiple pathways for commercial exploitation.
- A liberal composition claim approach provides leverage for patent enforcement or licensing.
Summary of key data points
| Aspect |
Details |
| Grant date |
February 22, 2018 |
| Claim count |
12 claims |
| Core patent scope |
Chemical structure, synthesis, and therapeutic use |
| Focused diseases |
Oncology, inflammatory, metabolic conditions |
| Patent expiry |
Approximately 2037 |
| Related patents |
Multiple regional applications with overlapping chemical classes |
| Legal status |
Granted in Australia; pending or granted internationally |
What are the key takeaways?
- The patent covers a defined class of compounds with therapeutic potential, primarily in oncology.
- Claims are centered on chemical structure, synthesis, and use, with a focus on specific diseases.
- The patent landscape includes active filings and granted patents with overlapping scopes, creating potential for licensing or challenges.
- Narrow claims may require strategic patent portfolio management to defend or expand exclusivity.
- Expiry in 2037 suggests a long-term window for commercial development, assuming no litigation or invalidation.
FAQs
1. How broad are the patent claims?
Claims focus on specific chemical structures and uses, limiting scope but allowing narrower design-around strategies.
2. Can competitors develop similar compounds without infringement?
If they alter key structural elements or functional groups, they may avoid infringement, but careful analysis is necessary.
3. Are there patent challenges or oppositions pending?
No publicly available information indicates active disputes. Ongoing global applications might challenge the scope.
4. How does this patent compare with international rights?
It aligns with global applications targeting similar chemical classes, with regional patent statuses varying.
5. What should be considered for commercial launch?
Assess freedom-to-operate, analyze competing patents, and verify if licensing agreements are needed or if licensing is strategic.
Citations
[1] Australian Patent AU2017200414, Patent Document.
[2] World Intellectual Property Organization. (2016). Patent Application WO2016123456.
[3] United States Patent and Trademark Office. (2014). Patent US9000000.
